- Home
- / Juniper Pharmaceuticals
- / Financials
Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
Juniper Pharmaceuticals financials data including stock price, CreditSafe score, income statement, balance sheet, and cash flow.
Revenue
$50 M
FY, 2017
CreditSafe Score
?
Score changed on Jul 24, 2026
Premium Content only available in Craft’s Intelligence Portal
View 30+ financial ratio metrics including price-to-earnings ratio, debt-to-assets ratio, gross profit margin, and more.
Financial ratio metrics help evaluate the financial strength of a company, and help raise red flags that can indicate potential risk, fulfillment challenges, or even possible bankruptcy.
Learn moreFinancial Statements
| USD | FY, 2012 | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 | FY, 2017 |
|---|---|---|---|---|---|---|
| Revenue | 25.8M | 29.2M | 32.5M | 37.6M | 54.6M | 50.0M |
| Revenue growth, % | 11.1% | 15.7% | 45.3% | |||
| Cost of goods sold | 12.8M | 13.3M | 17.7M | 21.4M | 24.3M | 29.0M |
| Gross profit | 13.0M | 16.0M | 14.8M | 16.1M | 30.3M | 21.0M |
| Gross profit margin, % | 50.5% | 54.7% | 45.5% | 43.0% | 55.5% | 42.1% |
| General and administrative expense | 8.6M | 8.0M | 8.6M | 10.5M | 14.1M | 15.4M |
| Operating expense total | 10.2M | 10.1M | 11.0M | 18.7M | 25.0M | 24.9M |
| EBIT | 2.8M | 5.9M | 3.8M | (2.5M) | 5.3M | (3.9M) |
| EBIT margin, % | 10.9% | 20.1% | 11.8% | -6.7% | 9.7% | -7.7% |
| Interest expense | 118.0K | 106.0K | 97.0K | 130.0K | ||
| Pre tax profit | 9.9M | 6.7M | 4.4M | (2.1M) | 6.0M | (2.2M) |
| Income tax expense | 22.6K | 988.0K | 5.0K | 91.0K | (186.0K) | |
| Net Income | 9.9M | 6.7M | 3.4M | (2.1M) | 6.0M | (2.1M) |